Meeting
2014 Genitourinary Cancers Symposium
Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
Authors
Elizabeth R. Plimack
Fox Chase Cancer Center, Philadelphia, PA
Elizabeth R. Plimack , Yu-Ning Wong , Lois Malizzia , Alycia Corrigan , Anthony J. Olszanski , Crystal Shereen Denlinger , Susan Roethke , Colleen H. Tetzlaff , Gary R. Hudes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01169532
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 501)
DOI
10.1200/jco.2014.32.4_suppl.501
Abstract #
501
Poster Bd #
G16
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
First Author: Matthew R. Zibelman
Poster
2014 ASCO Annual Meeting
Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
First Author: Evanthia Galanis
Poster
2013 Breast Cancer Symposium
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2013 ASCO Annual Meeting
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James